The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Stephen Burley named leader of cancer pharmacology research at Rutgers Cancer Institute of New Jersey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

STEPHEN BURLEY was named as co-program leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey.

Burley will work with co-program leader X.F. Steven Zheng, a university professor at Rutgers Robert Wood Johnson Medical School, in determining the mode of action and mechanism of resistance to anti-cancer agents and developing novel concepts and strategies for cancer treatment.

Burley has been a full research member of Rutgers Cancer Institute since 2013. He is the director of the Center for Integrative Proteomics Research, founding director of the Institute for Quantitative Biomedicine, and a distinguished professor of chemistry and chemical biology in the School of Arts and Sciences at Rutgers University. He also serves as director of the Research Collaboratory Structural Bioinformatics Protein Data Bank.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account